This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.

The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

A method for enhancing the enzymatic efficiency of an enzyme added to poultry feed for a living subject, comprises adding a cellulose-degrading enzyme to a mobile enzyme sequestration platform (MESP) so as to form an enzyme-MESP complex; adding the enzyme-MESP complex to poultry feed for a living subject; the enzyme efficiency of the cellulose-degrading enzyme of the enzyme-MESP complex after being exposed to a first adverse environment for a first period of time is at least 50% higher than the enzyme efficacy of the cellulose-degrading enzyme independent of the MESP being exposed to the first adverse environment for the first period of time.

A method for enhancing the enzymatic efficiency of an enzyme added to poultry feed for a living subject, comprises adding a cellulose-degrading enzyme to a mobile enzyme sequestration platform (MESP) so as to form an enzyme-MESP complex; adding the enzyme-MESP complex to poultry feed for a living subject; the enzyme efficiency of the cellulose-degrading enzyme of the enzyme-MESP complex after being exposed to a first adverse environment for a first period of time is at least 50% higher than the enzyme efficacy of the cellulose-degrading enzyme independent of the MESP being exposed to the first adverse environment for the first period of time.

An automated system of reactors carries out a solid-phase peptide synthesis, and more particularly a solid-phase peptide synthesizer which is automated, by means of a reactor with a liquid-recirculation loop making it possible to measure, in real time, chemical species in the reactor via measuring cells. This system includes inlet pipes, namely: pipes dedicated to the introduction of resin, pipes dedicated to the introduction of the synthesis and washing solvent, pipes dedicated to the introduction of the agent for deprotecting the amino acid introduced, pipes dedicated to the introduction of the reagents, and includes an assembly reactor and a loop for recirculation of the liquid of the reactor.

The present disclosure provides for non-viral compositions and methods for delivering nucleic acids into eukaryotic cells (e.g., stem cells) with high efficiency and low genotoxicity.

The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

Disclosed herein are methods of cancer treatment comprising administration of a natural killer (NK) cell or cell line in combination with an IL-6 antagonist, such as an antibody to IL-6 or its receptor, especially for treatment of cancer expressing IL-6 receptors and in which checkpoint inhibitory receptors, such as PDL-1 and/or PDL-2 are expressed/upregulated during disease.

Disclosed herein are methods of cancer treatment comprising administration of a natural killer (NK) cell or cell line in combination with an IL-6 antagonist, such as an antibody to IL-6 or its receptor, especially for treatment of cancer expressing IL-6 receptors and in which checkpoint inhibitory receptors, such as PDL-1 and/or PDL-2 are expressed/upregulated during disease.

The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.